Spironolactone improved cardiac structure and function in HFpEF, reducing left atrial volume index by 1.1 ml/m2 (95% CI -2.0 to -0.1; p=0.03) and left ventricular mass index by 3.6 g/m2 (p=0.01).
Meta-Analysis (n=984)
Yes
Does spironolactone improve echocardiographic parameters of cardiac structure and function in patients with HFpEF?
Spironolactone significantly improves key echocardiographic parameters of cardiac structure and function in patients with HFpEF over 9-12 months.
Effect estimate: Mean difference -1.1 ml/m2 (LAVi) (95% CI -2.0 to -0.1)
p-value: p=0.03
Abstract Aims Spironolactone is currently used in a large proportion of patients with heart failure and preserved ejection fraction (HFpEF), yet its effect on cardiac structure and function in a large population has not been well established. The aim of this study was to evaluate the impact of spironolactone on key echocardiographic parameters in HFpEF. Methods and results An individual-patient-data meta-analysis of three randomized trials (HOMAGE, Aldo-DHF, and TOPCAT) was performed comparing spironolactone (9–12 month exposure) to placebo (or control) for the changes in left atrial volume index (LAVi), left ventricular mass index (LVMi), interventricular septum (IVS) thickness, E/e′ ratio, and left ventricular ejection fraction (LVEF) among patients with stage B (HOMAGE) or C (Aldo-DHF and TOPCAT) HFpEF. Analysis of covariance was used to test the effect of spironolactone on echocardiographic changes. A total of 984 patients were included in this analysis: 452 (45.9%) from HOMAGE, 398 (40.4%) from Aldo-DHF, and 134 (13.6%) from TOPCAT. The pooled-cohort patient's median age was 71 (66–77) years and 39% were women. Median LAVi was 29 (24–35) ml/m2, LVMi 100 (84–118) g/m2, IVS thickness 12 (10–13) mm, E/e′ ratio 11 (9–13), and LVEF 64 (59–69)%. Spironolactone reduced LAVi by −1.1 (−2.0 to −0.1) ml/m2 (p = 0.03); LVMi by −3.6 (−6.4 to −0.8) g/m2 (p = 0.01); IVS thickness by −0.2 (−0.3 to −0.1) mm (p = 0.01); E/e′ ratio by −1.3 (−2.4 to −0.2) (p = 0.02); and increased LVEF by 1.7 (0.8–2.6)% (p 0.01). No treatment-by-study heterogeneity was found except for E/e′ ratio with a larger effect in Aldo-DHF and TOPCAT (interaction p 0.01). Conclusions Spironolactone improved cardiac structure and function of patients with HFpEF.
Ferreira et al. (2022) conducted a meta-analysis in Heart failure and preserved ejection fraction (HFpEF) (n=984). Spironolactone vs. Placebo (or control) was evaluated on Changes in left atrial volume index (LAVi), left ventricular mass index (LVMi), interventricular septum (IVS) thickness, E/e' ratio, and left ventricular ejection fraction (LVEF) (Mean difference -1.1 ml/m2 (LAVi), 95% CI -2.0 to -0.1, p=0.03). Spironolactone improved cardiac structure and function in HFpEF, reducing left atrial volume index by 1.1 ml/m2 (95% CI -2.0 to -0.1; p=0.03) and left ventricular mass index by 3.6 g/m2 (p=0.01).